DLK Investment Management LLC Has $4.98 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

DLK Investment Management LLC decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 0.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 19,104 shares of the medical research company’s stock after selling 120 shares during the quarter. Amgen makes up about 2.1% of DLK Investment Management LLC’s holdings, making the stock its 20th biggest position. DLK Investment Management LLC’s holdings in Amgen were worth $4,979,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. M.E. Allison & CO. Inc. bought a new stake in shares of Amgen during the fourth quarter valued at approximately $388,000. Willner & Heller LLC boosted its position in Amgen by 81.9% in the fourth quarter. Willner & Heller LLC now owns 2,925 shares of the medical research company’s stock valued at $762,000 after buying an additional 1,317 shares in the last quarter. Mechanics Bank Trust Department grew its position in Amgen by 1.4% during the 4th quarter. Mechanics Bank Trust Department now owns 7,854 shares of the medical research company’s stock worth $2,047,000 after acquiring an additional 105 shares during the last quarter. Diversify Wealth Management LLC increased its stake in shares of Amgen by 46.5% in the fourth quarter. Diversify Wealth Management LLC now owns 6,809 shares of the medical research company’s stock valued at $1,786,000 after buying an additional 2,162 shares in the last quarter. Finally, Guardian Investment Management raised its stake in shares of Amgen by 29.5% in the fourth quarter. Guardian Investment Management now owns 18,358 shares of the medical research company’s stock worth $4,785,000 after acquiring an additional 4,179 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on AMGN. Barclays lifted their price target on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Piper Sandler Companies reissued an “overweight” rating and set a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Citigroup cut their price target on Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Royal Bank of Canada reduced their target price on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a report on Wednesday, November 27th. Finally, Robert W. Baird reaffirmed an “underperform” rating and set a $215.00 price target on shares of Amgen in a research report on Wednesday, September 25th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Amgen currently has an average rating of “Hold” and an average target price of $314.91.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $272.11 on Monday. The company has a market capitalization of $146.27 billion, a PE ratio of 34.84, a PEG ratio of 2.68 and a beta of 0.56. The business has a fifty day moving average price of $273.95 and a 200-day moving average price of $307.20. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the previous year, the business posted $4.96 earnings per share. As a group, equities analysts expect that Amgen Inc. will post 19.57 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.50%. Amgen’s dividend payout ratio is 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.